©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
A Reevaluation of the Cap-binding Protein, eIF4E, as a Rate-limiting Factor for Initiation of Translation in Reticulocyte Lysate (*)

(Received for publication, November 2, 1995; and in revised form, January 23, 1996)

Michael Rau Theophile Ohlmann (§) Simon J. Morley (¶) Virginia M. Pain (**)

From the Department of Biochemistry, The University of Sussex, Falmer, Brighton BN1 9QG, United Kingdom

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The cap-binding eukaryotic initiation factor, eIF4E, is a key target for the regulation of translation in mammalian cells and is widely thought to be present at very low molar concentrations. Here we present observations with the reticulocyte lysate that challenge this view. When reticulocyte ribosomes are harvested by centrifugation, most (75%) of the eIF4E remains in the postribosomal supernatant (PRS). In a reconstituted translation system we find that the ribosome-associated eIF4E alone can sustain much of the overall activity, suggesting that much of the factor in the PRS is functionally redundant. Consistent with this, our estimates of eIF4E in the reticulocyte lysate reveal much higher concentrations than previously reported. The association of a small proportion of eIF4E with the ribosome fraction appears to be functional and dependent on interaction with the factor eIF4G. This fraction of eIF4E is, as expected, more highly phosphorylated than that in the PRS; however, at least half the total phosphorylated eIF4E in reticulocyte lysate translation systems resides in the PRS fraction, suggesting that, while phosphorylation may enhance activity, it is not in itself sufficient to promote utilization of the factor. We also show that the eIF4E-binding factor, eIF4E-BP1 or PHAS-I, which regulates eIF4E activity in insulin-responsive cells, is present in the reticulocyte PRS at an approximately 1:1 molar ratio relative to eIF4E and demonstrate by co-immunoprecipitation studies that the binding of PHAS-I and eIF4G to eIF4E is mutually exclusive. These data are consistent with a potential regulatory role for PHAS-I in the reticulocyte lysate.


INTRODUCTION

Translation of cellular mRNAs occurs by a cap-dependent mechanism whereby the 40 S ribosomal subunit interacts with the 5`-terminal cap structure and subsequently migrates to the AUG start codon(1, 2) . This process involves the activities of a number of protein factors of the eIF4 (^1)group(3, 4, 5) . The formation of the complex termed eIF4F is thought to allow joining of the ribosomal subunit to mRNA through its interaction with the mRNA cap structure on the one hand and association with ribosomes on the other(6) . eIF4F consists of three polypeptides(7, 8, 9) : (i) eIF4E, which specifically binds the cap; (ii) eIF4A, which possesses RNA helicase activity; and (iii) eIF4G, a 220-kDa polypeptide on SDS gels. There is a strong requirement for eIF4E and eIF4G in cap-dependent initiation(1, 10, 11, 12, 13) . Recent work has shed light on the potential role of eIF4G in translation initiation(14, 15) . These studies have identified an eIF4E-binding motif on eIF4G and have also identified likely sites of interaction with eIF4A and eIF3. Thus eIF4G seems to mediate joining of the mRNA and ribosomes by interaction with both the cap-binding protein, eIF4E, and with eIF3 already bound to ribosomes. eIF4A is believed to catalyze the unwinding of upstream mRNA secondary structures. It is recycled through the eIF4F complex during successive rounds of initiation(6, 16, 17) , possibly explaining the presence of, and requirement for, abundant quantities of uncomplexed eIF4A protein (6, 8, 18) . The unwinding activity of eIF4A is stimulated in the presence of eIF4B which may interact directly with mRNA(19, 20, 21, 22) and/or 18 S rRNA (23) through RNA recognition motifs.

eIF4E has been the focus of intensive study in recent years. Current data suggest that this factor exists in particularly low abundance both in the reticulocyte lysate (24, 25) and in HeLa cells(26) , indicating that it may quantitatively limit translation rates. The biological importance of eIF4E levels is illustrated by in vivo overexpression experiments, which result in a transformed phenotype (27) or aberrant growth(28) . Several observations stress the importance of eIF4E phosphorylation in regulation of eIF4E activity during cell growth and development (see Rhoads (5) and references therein)(29, 30, 31) . Growth stimulation correlates with increased de novo phosphorylation of eIF4E (reviewed in Rhoads (5) and Morley(31) ) and eIF4F complex formation(30, 31, 32, 33, 34) , while the reverse applies when translation rates are down-regulated during mitosis(35) , the heat-shock response (26, 36) and viral infection(37, 38) . Recent work has determined that the primary site of eIF4E phosphorylation in reticulocytes (39) and CHO cells (40) is serine 209. Interestingly, Saccharomyces cerevisiae and plant homologs of eIF4E lack a serine at the equivalent position (41, 42) (for comparison, see Hernández and Sierra(43) ). The effect of phosphorylation on the affinity of eIF4E for cap structures and components of the translation machinery remains uncertain. While hyperphosphorylation of eIF4E does not affect its recovery from HepG2 cell extracts on m^7GTP-Sepharose(32) , other experiments do suggest an enhanced affinity for cap analogs and mRNA(44) . eIF4E recovered with eIF4G from Ehrlich ascites tumor cells is highly phosphorylated relative to uncomplexed eIF4E(45) ; however, the phosphorylation of eIF4E alone may not alter its affinity for other elements of the translational apparatus(15, 32) .

It is now becoming clear that eIF4E interacts specifically with both eIF4G and at least one other binding protein, PHAS-I (also known as eIF4E-BP1)(15, 46, 47, 48, 49) . Current evidence suggests that PHAS-I acts to sequester eIF4E protein. In hormone-responsive cells phosphorylation of PHAS-I in response to insulin results in the release of sequestered eIF4E, thereby relieving inhibition of translation(47) . Further work has shown that PHAS-I and eIF4G possess a common eIF4E-binding motif (15) and indeed compete for binding to eIF4E(50) . Thus PHAS-I suppresses eIF4E activity by impairing its ability to form active complexes in association with eIF4G. Whether translation regulation by PHAS-I is important in reticulocytes is unknown at present.

In this report we present data indicating that, contrary to previous impressions, the reticulocyte lysate contains a functional excess of eIF4E. The small proportion of the factor associated with ribosomes in actively translating lysates shows enhanced phosphorylation. In addition we provide evidence that levels of eIF4E in the reticulocyte lysate are significantly higher than previously published and that the molar relationship of eIF4E to PHAS-I in the postribosomal supernatant is close to 1:1, supporting a regulatory role for PHAS-I in the reticulocyte lysate.


EXPERIMENTAL PROCEDURES

Materials

All reagents were reagent grade and purchased from Sigma unless indicated otherwise.

Buffers

Buffer A, 40 mM Tris/HCl, pH 7.4, 0.25 mM dithiothreitol, 0.1 mM EDTA, 50 mM sodium fluoride, 20 mM beta-glycerophosphate, 2 mM benzamidine, 0.05% (v/v) Tween 20, 10% (v/v) glycerol; Buffer B, 40 mM Mops/KOH, pH 7.2, 125 mM NaCl, 2.5 mM EGTA, 40 mM beta-glycerophosphate, 40 mM sodium fluoride, 0.5 mM phenylmethylsulfonyl fluoride, 2 mM benzamidine, 7 mM beta-mercaptoethanol; Resuspension buffer (RB), 20 mM Mops/KOH, pH 7.2; 10 mM NaCl; 1.1 mM MgCl(2); 0.1 mM EDTA; 75 mM KCl; 0.5 mM dithiothreitol; 5% (v/v) glycerol; RIPA, 50 mM Tris/HCl, pH 8.0, 1% (v/v) Triton X-100, 1% (v/v) Nonidet P-40, 0.1% (w/v) SDS, 125 mM NaCl, 10 mMp-nitrophenyl phosphate, 1 µM microcystin (Calbiochem), 2 mM benzamidine, 0.5 mM phenylmethylsulfonyl fluoride; Low salt buffer (LSB), 20 mM Mops/KOH, pH 7.2, 10 mM NaCl, 25 mM KCl, 1.1 mM MgCl(2), 0.1 mM EDTA, 0.5 mM dithiothreitol; IEF sample buffer, 9 M urea, 7% (v/v) Ampholine, pH 3.5-10 (Pharmacia Biotech Inc.), 2% (v/v) beta-mercaptoethanol, 5% (w/v) CHAPS, 1 µM microcystin (Calbiochem).

m^7GTP-Sepharose Chromatography

Prior to use, the m^7GTP-Sepharose affinity resin (Pharmacia) was equilibrated in RB, and the buffer was removed by aspiration using a needle attached to a vacuum line. Depletion of eIF4E was achieved in batch by addition of 4.5 volumes of undiluted reticulocyte lysate onto 1 volume of m^7GTP-Sepharose, gentle agitation on ice for 15 min, and recovery of the unbound fraction by a brief centrifugation in a microcentrifuge. In all cases, unbound material from a parallel treatment using Sepharose 4B was used as the nondepleted control.

In Vitro Translation

Reticulocyte lysates were prepared as described(51) . Translation reactions contained 50% (v/v) reticulocyte lysate with the following added components (final concentrations): 25 µM hemin, 25 µg/ml creatine phosphokinase, 75 mM KCl, 0.8 mM magnesium acetate, 50 µM amino acids without methionine and leucine, 200 µM leucine, 3 mMD-glucose, 5 mg/ml creatine phosphate. The translational activity of the system was measured by inclusion of 0.1 mCi/ml [S]methionine and measurement of trichloroacetic acid-precipitable radioactivity by scintillation counting.

Fractionation and Reconstitution of the Reticulocyte Lysate

Ribosomal components of the intact reticulocyte lysate were separated from the soluble fraction by centrifugation at 100,000 rpm (approximately 430,000 times g) for 25 min at 4 °C using the TL-100.2 rotor in a Beckman TL-100 ultracentrifuge, essentially as described elsewhere(52) . When required for subsequent translation assays, the undiluted reticulocyte lysate was used as the starting material and the top two-thirds of the postribosomal supernatant removed for use, while the bottom third of the supernatant was discarded. The ribosomal pellet was resuspended in RB buffer to 0.1 of the starting volume, yielding a 10-fold concentrated (10times) stock of ribosomes. For reconstitution, 0.45 volume of postribosomal supernatant was combined with 0.05 volume of 10times ribosomes in a 50% translation reaction as above, with the additional inclusion of 15 mM 2-aminopurine. For measurements of the subcellular distribution of translation factors (see ``Results and Discussion'') the reticulocyte lysate was preincubated under full translation conditions (as above) prior to ultracentrifugation. In these cases the ribosomal pellet was resuspended in RB buffer to 0.2 of the volume of the original incubation.

Purification of eIF4E by Fast Protein Liquid Chromatography

Chromatography on Mono Q (Pharmacia) to separate the reticulocyte lysate into fractions enriched in eIF4F or eIF4E was based on the method of Lamphear and Panniers(45) , with some modifications. Briefly, 700 µl of reticulocyte lysate previously incubated for 15 min under full translation conditions was loaded onto a 1-ml Mono Q column equilibrated with 10 ml of Buffer A containing 50 mM KCl. The ``free'' and complexed forms of eIF4E were step-eluted with Buffer A containing 130 mM KCl and 330 mM KCl, respectively. Pooled eluates were diluted to 100 mM KCl by addition of KCl-free Buffer A and eIF4E purified by affinity chromatography using a 0.3 ml m^7GTP-Sepharose column, previously equilibrated in Buffer B. Bound eIF4E was eluted in 0.5 ml of Buffer B containing 150 µM m^7GTP, concentrated by acetone precipitation and the sample dissolved directly into IEF sample buffer (see above).

Co-immunoprecipitation

Following preincubation under full translational conditions, 40 µl of translation mix was brought to 200 µl with RIPA prior to addition of affinity purified polyclonal antiserum as indicted in the figures. The mixture was incubated on ice for 90 min and IgG recovered by addition of 50 µl of a 50% (v/v) Protein A-Sepharose 4B suspension (Pharmacia) in RIPA. Following agitation at 4 °C for 30 min, the resin was recovered by centrifugation, washed three times in 1 ml of RIPA and bound proteins eluted directly into SDS or IEF sample buffer, as indicated in the figure legends.

Expression and Purification of Recombinant eIF4E, [His](6)-tagged PHAS-I, and L Protease

Recombinant proteins were expressed in, and purified from, Escherichia coli (BL21(DE(3)) strain containing the plasmid pLysS (Novagen)) as described for eIF4E(53) , PHAS-I(54) , and L protease (Lb)(55) . In the final step of purification, recombinant protein was dialyzed overnight at 4 °C against LSB and the protein concentration measured by the Bradford assay (Bio-Rad).

SDS-Polyacrylamide Gel Electrophoresis (PAGE)

Samples were analyzed on 12% polyacrylamide mini-gels (Protean II, Bio-Rad) as described elsewhere(33) .

Vertical Slab Isoelectric Focusing (VSIEF)

One-dimensional VSIEF of eIF4E was carried out essentially as described previously (53) using a Protean II mini-gel apparatus (Bio-Rad). Briefly, samples were combined with at least one volume of IEF sample buffer before focusing on a 5.6% acrylamide gel for 3 h at 500-750 V (50 V increments, every 30 min) in the presence of 9 M urea, 7.5% (v/v) Ampholine, pH 3.5-10, and 2% (w/v) CHAPS. 0.01 M histidine was used at the cathode (outer chamber) and 0.05 M glutamic acid at the anode (inner chamber).

Western Blotting

After SDS-PAGE or VSIEF, proteins were transferred to polyvinylidene difluoride membrane (Immobilon P, Millipore) under semidry conditions (Semi-Phor, Hoefer Scientific Instruments). Blots were incubated with primary antiserum; eIF4G, polyclonal rabbit anti-peptide, raised against the N-terminal sequence KKEAVGDLLDAFKEVN; eIF4E, polyclonal rabbit anti-peptide, raised against the peptide WALWFFKNDKSKTWQANL; PHAS-I, polyclonal rabbit anti-peptide raised against the peptide CSSPEDKRAGGEESQFE(46) ; eIF4B, polyclonal goat anti-eIF4B protein antiserum, kindly provided by Dr. J. Hershey; eIF4A, monoclonal antiserum, the kind gift of Dr. M. Altmann. Bands were revealed by incubation with the appropriate alkaline phosphatase-conjugated secondary antibody. Anti-peptide antibodies were affinity purified on Affi-Gel 10 (Bio-Rad) prior to use, in accordance with the manufacturers instructions.


RESULTS AND DISCUSSION

The availability of eIF4E is widely believed to limit translation in eukaryotic cells(5, 49) . This belief is based on measurements of initiation factor concentrations in HeLa cells (26) and reticulocytes (24, 25) , which indicated a very low ratio of eIF4E to ribosomes. However, another common observation is that eIF4E is found in cells in both low and high molecular weight forms(33, 45, 56) . The latter, which is usually isolated from ribosomal salt-wash fractions, is a complex of eIF4E with other initiation factors, notably eIF4A and eIF4G, which together make up the eIF4F complex(7, 9) . This is believed to be the functional form of eIF4E, and good correlations between rates of protein synthesis and the proportion of eIF4E associated with these complexes have been observed in a number of physiological states(30, 33, 34) . In contrast, isolation of eIF4E from cytosolic (postribosomal supernatant) fractions of cells by m^7GTP-Sepharose affinity chromatography invariably yields the low molecular weight form(9, 57, 58) , suggesting that cells contain substantial amounts of the factor not involved in protein synthesis(45) .

Much of the Endogenous eIF4E Can Be Removed from the Intact Reticulocyte Lysate with Only a Small Effect on Translational Activity

To examine the effect of partial depletion of eIF4E on protein synthesis we have employed the affinity matrix m^7GTP-Sepharose to specifically remove eIF4E from the rabbit reticulocyte lysate (RRL) in vitro translation system. To preclude concomitant removal of eIF4G, the post-ribosomal supernatant was first separated from the ribosomes and then subjected to treatment with the affinity resin, using a batch method. Separation of the ribosomal and postribosomal supernatant (PRS) fractions from small volumes of reticulocyte lysate can be achieved very rapidly using conditions previously established (52) (see also ``Experimental Procedures''). Ribosomal and PRS fractions can be reconstituted into a translation system that retains approximately 70% of the activity of the parental lysate and maintains polysome integrity in vitro (data not shown). Using the initiation inhibitor edeine, we find that the reconstituted translation system used here is 90% initiation-dependent; this value is only slightly below that for the intact reticulocyte lysate (data not shown). Fig. 1A shows Western blots demonstrating the degree of depletion of the PRS as well as the quantities of eIF4E remaining after reconstitution of the translation system with ribosomes (``incubation''). In the control incubation, the PRS was mock-depleted using Sepharose 4B resin (see ``Experimental Procedures''). Lanes 1 and 2 show that all detectable eIF4E was removed from the PRS following treatment with m^7GTP-Sepharose. The small proportion of eIF4E that reappeared upon reconstitution (lane 4) is attributable to the added ribosomes. The influence of this treatment on translation of endogenous mRNA in the reconstituted lysate system is shown in Fig. 1B. Surprisingly, despite the extensive removal of eIF4E (80-90%), only a 30% reduction in [S]methionine incorporation was observed after 60 min. Although the rate of translation is seen to fall relative to the undepleted control during the late part of the time course depicted in Fig. 1B, this was a characteristic of this experiment and was not a reproducible finding. Experiments in which the batch depletion was applied instead to the reconstituted system following recombination of the PRS with ribosomes consistently show an effect more in line with the extent of eIF4E depletion (data not shown). These results raise two interesting questions. First, the maintenance of approximately 70% of the protein synthesis activity in a system depleted of 80-90% of its content of eIF4E is not consistent with the concept that this factor is present in rate-limiting amounts(5, 25, 26, 49) ; rather it indicates that much of the factor in the PRS fraction is non-functional. This is consistent with the finding that eIF4E may be withheld from participation in initiation complexes through sequestration by PHAS-I in other cell systems(47, 48) . The second point relates to the more severe effect of depleting the reconstituted lysate, rather than the PRS alone, prior to reconstitution (data not shown). This result may be explained by the concomitant removal of eIF4G by the m^7GTP-Sepharose affinity matrix due to its interaction with eIF4E. Alternatively, the ribosomal fraction may contain a highly active (e.g. highly phosphorylated) form of eIF4E(59) , which is removed by depleting the reconstituted lysate. In order to address these points we have undertaken a more rigorous study of the distribution of eIF4E between the ribosome-associated and PRS fractions of actively translating reticulocyte lysates, and, for each population of the factor, we have analyzed its extent of phosphorylation and its association in complexes with eIF4G and PHAS-I.


Figure 1: Extensive depletion of eIF4E in the reticulocyte lysate causes only a moderate inhibition of protein synthesis. A, the PRS of a reticulocyte lysate was subjected to batchwise treatment with either Sepharose 4B (Control) or the affinity matrix m^7GTP-Sepharose 4B (Depleted) for 15 min on ice as described under ``Experimental Procedures.'' Samples corresponding to 1 µl of the parent reticulocyte lysate were analyzed by SDS-PAGE and the depletion of eIF4E monitored by immunoblotting, as described (PRS, lanes 1 and 2). In addition, equivalent samples were analyzed in a similar manner following reconstitution of the reticulocyte lysate (see below) (Incubation, lanes 3 and 4). The immunoblots were quantified by scanning densitometry and the data are presented as a histogram of optical density expressed as arbitrary units (AU). B, control and depleted postribosomal supernatant (0.45 volume) were recombined with resuspended 10times ribosomes (0.05 volume) and translation mix (0.5 volume) prior to incubation at 30 °C. Aliquots (2 µl) were removed at the times shown and processed for incorporation of [S]methionine into acid-precipitable protein. These data are representative of those obtained in three separate experiments.



Subcellular Distribution of eIF4E and Associated Proteins in the Reticulocyte Lysate

Fig. 2A shows the results of an experiment where an intact RRL was incubated for 15 min at 30 °C under full translational conditions (see ``Experimental Procedures'') and subsequently separated into soluble (PRS) and ribosomal fractions. The complete removal of all ribosomal components from the PRS was confirmed by sucrose density gradient analysis (data not shown). Equivalent samples of PRS and resuspended ribosomes were analyzed by gel electrophoresis followed by Western blotting, using antibodies recognizing eIF4E, eIF4G, eIF4B, eIF4A, and PHAS-I (see ``Experimental Procedures''). The intensity of the resultant bands was quantified by densitometry and these data are summarized in Table 1. In all cases the immunochemical signal of the blot was within the linear range of antibody response (data not shown). The distribution of the various proteins differed substantially; approximately 80% of the total eIF4G co-sedimented with ribosomes, while only about 25% of total eIF4E and no detectable PHAS-I were found in this fraction. In contrast both eIF4B and eIF4A were fairly evenly distributed between both the PRS and ribosomal fractions. The presence of most of the eIF4E in the PRS, apparently not directly associated with the translational machinery in the ribosomal fraction, may be explained by sequestration into inactive complexes by specific binding proteins such as PHAS-I(47, 48, 60, 61) . Indeed our unpublished results show that removal of eIF4E from the PRS using mGTP-Sepharose concomitantly removes PHAS-I, indicating a stable interaction between eIF4E and PHAS-I in that fraction. The presence of about 80% of the eIF4G in the ribosome fraction suggests that this factor, rather than eIF4E, may be limiting for translation, although it is possible that the association of eIF4G with ribosomes is independent of active protein synthesis. Indeed, Joshi et al.(62) have demonstrated association of radioactively labeled eIF4G with 43S preinitiation complexes in reticulocyte lysates, suggesting that the factor binds to ribosomes in the absence of mRNA.


Figure 2: Subcellular distribution of eIF4E and associated proteins in the reticulocyte lysate; effects of cleavage of eIF4G by L protease. A, following a 15-min preincubation at 30 °C under full translation conditions (see ``Experimental Procedures'') reticulocyte lysate was rapidly fractionated by centrifugation at 100,000 rpm (approximately 430,000 times g) for 25 min in a Beckman TL-100 centrifuge. The S 100 was removed (PRS), and the pellet was resuspended in RB buffer on ice to 0.2 of the original incubation volume (see ``Experimental Procedures''). Samples corresponding to 1 µl of unfractionated reticulocyte lysate were analyzed by SDS-PAGE and Western blotting using the specific antibodies shown. B, the reticulocyte lysate was further incubated for 10 min at 30 °C following the addition of a partially purified form of recombinant FMDV L protease prior to fractionation and immunoblot analysis as for A. Cp = eIF4G cleavage product, N-terminal domain; Cp = eIF4G cleavage product, C-terminal domain. These data are representative of those obtained in three separate experiments.





The Association of eIF4E with Ribosomes Is Functional

In order to test the functional significance of eIF4E associated with ribosomes (Fig. 2A), we have employed the eIF4G-specific FMDV L protease as a tool to block the initiation phase of translation. The use of L protease in preference to other inhibitors of initiation allowed us to evaluate simultaneously the role of eIF4G in mediating the association of eIF4E with the ribosomal fraction. In the experiment shown in Fig. 2B, the reticulocyte lysate translation system was briefly incubated under protein synthesis conditions, followed by addition of L protease and a further incubation. The lysate was subsequently fractionated into PRS and ribosomal fractions as described and the distribution of initiation factors determined by SDS-PAGE and immunoblotting. Separate anti-peptide antibodies recognizing eIF4G were used to monitor the N-terminal (termed Cp(N)) and the C-terminal (Cp(C)) cleavage products (the latter a kind gift from Dr. R. Rhoads, Louisiana State University). A summary of the densitometric quantification of these Western blots is shown in Table 1. After L protease treatment of the reticulocyte lysate the C-terminal domain of eIF4G remains mostly ribosome-bound, while, in contrast, the N-terminal domain of eIF4G is released into the PRS (compare Fig. 2, A with B). Fig. 2B also demonstrates that the L protease treatment results in the complete loss of eIF4E from the ribosomal fraction, while the distribution of eIF4B, eIF4A, and PHAS-I is not affected. These observations suggest a functional role for the ribosome-bound eIF4E in the intact reticulocyte lysate, mediated by the N-terminal domain of eIF4G, rather than nonspecific binding or contamination of the ribosomal pellet by supernatant material. The data are therefore consistent with recent observations suggesting that the C-terminal domain of eIF4G interacts with eIF4A, eIF3, and ribosomes, while the N-terminal domain binds eIF4E(14, 15, 49, 63) . Thus in the presence of L protease the distribution of the C-terminal domain of eIF4G and eIF4A between the PRS and ribosomes remains unchanged, while there is a shift of the N-terminal domain and associated eIF4E into the soluble fraction.

The Removal of eIF4E from the Ribosomal Fraction by Treatment with L Protease Is Not Dependent on the Loss of Polysome Integrity

An outstanding question from the work detailed above is whether eIF4G cleavage directly causes the release of eIF4E from cap structures, or whether the movement of eIF4E into the soluble fraction, shown in Fig. 2, could be explained by a shift of mRNA itself into the PRS after ribosome run-off, with eIF4E remaining bound to the mRNA cap structure. In order to examine the latter possibility, we used the elongation inhibitor emetine to prevent ribosome run-off in the presence and absence of L protease. Lysates were incubated as described in Fig. 2B but in the presence of emetine to maintain polysomes (data not shown); lysates were then fractionated and the level of eIF4E associated with the ribosomal fraction analyzed by immunoblotting. Fig. 3shows that maintenance of polysome integrity does not prevent the release of ribosome-associated eIF4E into the postribosomal supernatant following L protease treatment. This intriguing result can be explained by at least three distinct mechanisms. First, if all ``ribosomal'' eIF4E is normally cap-associated, the most probable explanation for these data is that L protease-induced cleavage of eIF4G results in the dissociation of eIF4E from the mRNA cap. A cleavage-induced conformational alteration in the eIF4G domain containing the eIF4E-binding site may be transmitted to eIF4E itself, reducing its affinity for the cap structure. Although eIF4E alone does have a high affinity for mRNA cap structures in vitro(44) , this is apparently stimulated in the presence of eIF4G(4, 6, 19) ; hence, cleavage of eIF4G might conversely reduce its affinity for the cap. However, work in several laboratories, including our own, (^2)has shown that the Cp(N)bulleteIF4E complex retains its ability to bind to cap analogs(9, 14, 58) . A second alternative is that the association between eIF4E and the cap is very transient, with eIF4E being released from the cap as the 40S subunit begins to scan toward the initiation codon. In this model the eIF4E present in ``48 S'' complexes(62, 64) , where the 40 S subunit is presumably located at the initiation codon, would be attached solely via its interaction with eIF4G. Finally, one might argue that only a small proportion of ribosomal eIF4E is cap-associated and that the majority is in fact involved in 43 S preinitiation complexes formed in the absence of mRNA. eIF4E in such complexes, presumably bound via the N-terminal domain of eIF4G, would be released into the soluble fraction following cleavage of eIF4G. Prevailing evidence is against the presence of eIF4E in 43 S preinitiation complexes(62, 64) , but uncertainty on this point remains (65) .


Figure 3: Emetine does not prevent the loss of eIF4E from the ribosomal fraction following cleavage of eIF4G by L protease. Three parallel reactions of intact reticulocyte lysate under full translation conditions (see ``Experimental Procedures'') were incubated for 15 min at 30 °C. Emetine (25 µM final concentration) was added for 2 min where indicated, prior to the addition of recombinant L protease (or an equivalent volume of LSB) and the incubation continued for a further 10 min at 30 °C. Reactions were stopped by cooling on ice and lysates were fractionated by ultracentrifugation, as described in Fig. 2. The resultant ribosome pellets were resuspended as described and aliquots corresponding to 3 µl of undiluted reticulocyte lysate were analyzed by SDS-PAGE and the presence of eIF4E monitored by Western blotting. These data were reproduced on two separate occasions.



eIF4E in the Ribosomal Fraction of the Reticulocyte Lysate Is Highly Phosphorylated

There are strong circumstantial links between eIF4E phosphorylation and enhanced activity of this factor(5, 29, 30, 49) . Fig. 4A shows typical measurements of eIF4E phosphorylation obtained when samples of PRS and resuspended ribosomes are subjected to VSIEF followed by Western blotting (see ``Experimental Procedures''). Clearly, the small proportion of eIF4E that is ribosome-bound is enriched for the phosphorylated form. This effect is reproducible between lysates, although the actual degree of phosphorylation shows some variation. Nonetheless, it is noteworthy that first, we never observe 100% phosphorylation of ribosomal eIF4E and, second, the soluble eIF4E pool is itself approximately 30% phosphorylated. By combining data from Fig. 2A and Fig. 4A we can estimate the distribution of the phosphorylated form of eIF4E between subcellular fractions in the reticulocyte lysate (Table 2) and find that, while the ribosomal fraction is enriched for the phosphorylated form, the postribosomal supernatant contains more than half of the total phosphorylated eIF4E protein in the reticulocyte lysate. However, the PRS contains only small amounts of eIF4G (Fig. 2A). Hence, while phosphorylation of eIF4E may affect its ability to participate in protein synthesis, it cannot alone be sufficient to promote an association with eIF4G. Indeed, unpublished studies discussed by Mader et al.(15) have indicated that phosphorylation of eIF4E does not alter its interaction with eIF4G in a far Western blotting assay. Rather, concomitant phosphorylation of eIF4E and eIF4G may be required to stimulate their interaction(32) .


Figure 4: The phosphorylation status of eIF4E in subcellular fractions of the reticulocyte lysate. A, the intact reticulocyte lysate was incubated for 15 min at 30 °C prior to centrifugal fractionation into PRS and ribosomes. The following samples were then removed for VSIEF, and the proportion of total eIF4E in the phosphorylated state was visualized by immunoblotting: 4 µl of the original incubation, corresponding to 2 µl of reticulocyte lysate; PRS (4 µl); ribosomes (10 µl), corresponding to 5 µl of reticulocyte lysate. The upper band, indicated as P, corresponds to the phosphorylated form of eIF4E. In each case, quantification of these data by scanning yielded the percent of total eIF4E in the phosphorylated form. The data are representative of six independent experiments. B, reticulocyte lysate was incubated under full translation conditions as above prior to chromatography on Mono Q as described under ``Experimental Procedures.'' Material corresponding to uncomplexed eIF4E (Light) was eluted from the column at 130 mM KCl, while complexed eIF4E (Heavy) was eluted at 330 mM KCl. eIF4E was isolated as described under ``Experimental Procedures.'' Precipitated proteins were resuspended directly in IEF sample buffer and subjected to VSIEF. A sample of the Mono Q load, corresponding to 2 µl of reticulocyte lysate, was also analyzed (Starting material). Quantification by scanning yielded values for the percentage of phosphorylation. The data are representative of two separate experiments. C, reticulocyte lysate was incubated as in B; immunoprecipitation of eIF4E was carried out using affinity-purified antibodies recognizing eIF4G, eIF4E, and PHAS-I, as described under ``Experimental Procedures.'' Immune complexes were isolated with Protein A-Sepharose in batch, as described, and the bound protein eluted directly into IEF sample buffer. Starting material shows VSIEF analysis of 4 µl of the original translation incubation. These data are representative of four separate experiments.





eIF4E Involved in Complexes Is More Phosphorylated than the ``Free'' Form When These Are Separated by Fast Protein Liquid Chromatography

As an alternative approach to differentiating between populations of eIF4E in the reticulocyte lysate we used Mono Q chromatography to separate complexed from uncomplexed eIF4E in samples of actively translating reticulocyte lysate (see ``Experimental Procedures''), using a procedure similar to Lamphear and Panniers (45) . Pools corresponding to eIF4EbulleteIF4G complexes (``heavy'') and uncomplexed (``light'') fractions were analyzed by both SDS-PAGE (data not shown) and VSIEF (Fig. 4B). In support of the data obtained with fractions separated by ultracentrifugation (Fig. 2A), approximately 80% of the eIF4E was recovered at a KCl concentration previously found to elute the uncomplexed form of eIF4E protein(45) , while 20% showed elution properties typical of the eIF4EbulleteIF4G complex (data not shown). This latter fraction was, however, more highly phosphorylated (60%) (Fig. 4B). These data thus support those in Fig. 4A, indicating that the functional pool of eIF4E is enriched for, but does not contain exclusively, the phosphorylated form of the protein.

Anti-eIF4G Antibody Co-immunoprecipitates Mostly Phosphorylated eIF4E, while Anti-PHAS-I Antibody Co-immunoprecipitates eIF4E That Is Less Phosphorylated

To confirm data on the phosphorylation status of eIF4E in complexed versus ``free'' form (Fig. 4, A and B), we examined the phosphorylation status of eIF4E in immunoprecipitates obtained with antibodies against eIF4E, eIF4G, and PHAS-I (see ``Experimental Procedures''). Fig. 4C shows that, relative to the starting material (31% phosphorylated) or that recovered with anti-eIF4E antibody (29% phosphorylated), eIF4E co-immunoprecipitating with anti-eIF4G antibody is more highly phosphorylated (54%). However, the eIF4E co-immunoprecipitating with anti-PHAS-I antibody appears, if anything, to be less phosphorylated (20%) than the starting material.

Thus we find that eIF4E, selected by three distinct methods (Fig. 4, A-C), on the basis of its association with active translational complexes, is consistently enriched for the phosphorylated form. This observation supports the large body of evidence (5, 29, 30) which correlates increased eIF4E phosphorylation with enhanced eIF4E activity. While there is in vitro evidence for a greater affinity of phosphorylated eIF4E for mRNA cap structures(44) , it is not clear at this stage which aspect(s) of eIF4E activity are affected by its phosphorylation in vivo. Numerous studies linking increased eIF4E phosphorylation and enhanced complex/eIF4F formation (30, 32, 33, 34) would indicate an improved ability to bind eIF4G; however, no evidence has been presented to refute the alternative possibility that eIF4E phosphorylation occurs only as a consequence of recruitment into complexes.

Binding of eIF4G or PHAS-I to eIF4E Is Mutually Exclusive

Recent work has provided evidence for a common eIF4E-binding motif within both eIF4G and PHAS-I(15) . This suggests a competitive scenario where PHAS-I and eIF4G are unable to interact with eIF4E simultaneously. Recent studies with purified proteins by Haghighat et al.(50) have provided evidence in support of this hypothesis. Most work in favor of an important regulatory role for PHAS-I in controlling protein synthesis has involved insulin-responsive cells(48, 60) . However, the potential role of PHAS-I in reticulocytes is not known at this time. As seen in Fig. 2A, we have detected significant quantities of PHAS-I in the reticulocyte lysate. Indeed the preferential retention of this protein in the post-ribosomal supernatant is consistent with current views for the role of PHAS-I which would preclude an association with any ribosomal component.

We have therefore extended the use of co-immunoprecipitation to investigate molecular interactions between eIF4G, eIF4E, and PHAS-I in the intact reticulocyte lysate under full translational conditions. Fig. 5shows Western blots of co-immunoprecipitated material following SDS-PAGE. While this procedure is not quantitative, each employed antiserum predictably precipitated its specific antigen. Fig. 5shows that, in addition, anti-eIF4G antibody co-immunoprecipitates eIF4E, while anti-eIF4E co-immunoprecipitates eIF4G and PHAS-I, and anti-PHAS-I antibody co-immunoprecipitates eIF4E. The doublet due to PHAS-I is likely to represent two differentially phosphorylated forms, as seen in 3T3-L1 cells(48, 60) . These data are internally consistent in their support for interactions between eIF4E and eIF4G, as well as between eIF4E and PHAS-I. However, the failure of anti-eIF4G antibodies to co-immunoprecipitate PHAS-I and, conversely, the absence of eIF4G in anti-PHAS-I immunoprecipitates, in spite of the presence of eIF4E in both cases, provides evidence for a mutually exclusive interaction of PHAS-I and eIF4G with eIF4E in reticulocytes. It is likely, therefore, that PHAS-I and eIF4G compete for available eIF4E, where the affinity of PHAS-I(47, 48, 60) , and possibly that of eIF4G, for eIF4E, is influenced by phosphorylation. These data are in agreement with recent work by Mader et al.(15) and Haghighat et al.(50) . While we have established that eIF4E phosphorylation is insufficient to explain association with eIF4G (see Fig. 2A and Fig. 4A, summarized in Table 2), it is not known whether the phosphorylation status of eIF4E influences its association with PHAS-I. Fig. 4C shows that eIF4E co-immunoprecipitated with PHAS-I antibody is only 20% phosphorylated, compared with a phosphorylation status of approximately 30% in the starting material. The significance of this small difference is not clear; whereas dephosphorylation of eIF4E might favor binding of PHAS-I, it may equally occur as a consequence of association with PHAS-I.


Figure 5: Analysis of protein-protein interactions by co-immunoprecipitation with affinity purified antibodies to eIF4G, eIF4E, and PHAS-I. For immunoprecipitation studies, reticulocyte lysate, under full translation conditions (40 µl), was incubated for 15 min at 30 °C before dilution to 200 µl in RIPA. Polyclonal affinity-purified antibodies, specific for eIF4G, eIF4E, and PHAS-I, were then added and incubated for 90 min at 4 °C. Immune complexes were purified with Protein A-Sepharose, and the bound protein was eluted directly into sample buffer for SDS-PAGE. Proteins were transferred to polyvinylidene difluoride, and eIF4G, eIF4E, and PHAS-I in the sample were visualized by immunoblotting. These data are representative of those obtained in four separate experiments.



The Molar Ratio of eIF4E to PHAS-I in the Postribosomal Supernatant of the Reticulocyte Lysate Is Approximately 1:1

To further assess the potential role of PHAS-I in the regulation of protein synthesis in reticulocyte lysates, we have estimated the molar concentrations of eIF4E and PHAS-I proteins in this system. To date, the only quoted estimate of the ratio of PHAS-I to eIF4E in the reticulocyte lysate is 1:20(47) , although no data were presented. We have used purified, recombinant eIF4E (Fig. 6) and PHAS-I (Fig. 7) proteins as standards in Western immunoblotting assays, using a procedure similar to that employed by Pause et al.(17) . Fig. 6A shows >90% purity of the recombinant eIF4E protein. Fig. 6B shows a Western blot demonstrating a linear immunological response to increasing levels of recombinant eIF4E. In the same experiment, three different volumes of reticulocyte lysate were used to estimate the average endogenous concentration of eIF4E (Fig. 6C). From these data we calculate that 1 ml of reticulocyte lysate contains approximately 10.7 ± 0.8 µg (S.D., n = 3) of eIF4E. Fig. 6D confirms this result by showing that 0.5 µl of reticulocyte lysate (lane 1) yields an immunological response similar to that observed with 5.5 ng of recombinant eIF4E (lane 3). A similar value was obtained in assays on three separate lysates (data not shown). In molar terms this value is equivalent to a concentration for eIF4E of 0.4 µM, as compared to previous estimates of 8 nM(24) and 33 nM(25) in the reticulocyte lysate and a calculated 0.35 nM in HeLa cells(26) . Consistent with eIF4A being one of the most abundant initiation factors(18, 26) , the recent estimation of 3.4 µM (calculated from 17) reveals eIF4A levels approximately 10-fold greater than those calculated above for eIF4E. Initiation factor concentrations are often best expressed relative to the translational apparatus itself. We have measured the molar concentration of ribosomes in different preparations of reticulocyte lysate and obtain a value of 0.2 µM ± 0.04 (S.D., n = 4). Thus we observe a eIF4E to ribosome ratio of 2:1 in reticulocytes, compared with previous data of 0.02 in reticulocytes (24) and 0.26 in HeLa cells(26) . Our revised estimates of eIF4E abundance are therefore significant in that they are at least an order of magnitude greater than those published to date. Furthermore, these estimates are consistent with observations published herein that quantities of eIF4E per se are not limiting for translation in the reticulocyte lysate (see Fig. 1) and that the majority of this protein is not engaged in translation under optimal conditions (see Fig. 2A).


Figure 6: Quantification of the levels of eIF4E protein in the reticulocyte lysate. A, recombinant, bacterially expressed eIF4E protein (2 µg), prepared as described under ``Experimental Procedures,'' was analyzed by SDS-PAGE and Coomassie staining; the resultant gel is presented. B, the immunological response to increasing amounts of recombinant eIF4E was tested by Western blotting (upper panel) and quantified by densitometric scanning (lower panel; AU = arbitrary units). C, the same experiment included a dose response of eIF4E antibodies to three different volumes of reticulocyte lysate. An estimation of eIF4E concentration in the reticulocyte lysate (see ``Results'') was made by taking the average of the calculated concentration, obtained from each of the three doses of reticulocyte lysate. D, to ensure reliability of the Western blotting method, 0.5 µl of reticulocyte lysate (lane 1) and 5.5 ng of recombinant eIF4E (lane 3) were tested for their ability to give an additive immunological response when combined (lane 2). These data are representative of those obtained in five experiments using three different lysate preparations.




Figure 7: Quantification of the level of PHAS-I protein in the reticulocyte lysate. A, recombinant histidine-tagged PHAS-I ([His^6]PHAS-I) was prepared as described under ``Experimental Procedures.'' The immunological response to increasing amounts of recombinant [His^6]PHAS-I was tested by Western blotting; the data were quantified by scanning and are presented on the lower panel as an optical density in arbitrary units (AU) expressed as a function of increasing amounts of PHAS-I (ng). B, the same experiment included a dose response of PHAS-I antibodies to three different volumes of reticulocyte lysate. An estimation of PHAS-I concentration in the reticulocyte lysate (see ``Results'') was made by taking the average of the calculated concentration, obtained from each of the three doses of reticulocyte lysate. Similar data were reproduced in two further experiments using different lysate preparations.



In Fig. 7, we show a similar method to quantify the concentration of PHAS-I in reticulocyte lysates. The recombinant PHAS-I protein used was electrophoretically distinct from endogenous PHAS-I, because of a histidine tag used to facilitate its purification (data not shown, see ``Experimental Procedures''). Assuming that the histidine tag had no influence on the immunoreactive properties of the recombinant protein, we estimate the concentration of PHAS-I to be 3.2 ± 0.4 µg/ml of reticulocyte lysate (S.D., n = 3) (see Fig. 7B), representing a molar concentration of 0.3 µM. From these data the ratio of eIF4E to PHAS-I in the reticulocyte lysate (and particularly in the PRS, containing 75% of total eIF4E and all endogenous PHAS-I) (see Fig. 2A) is close to 1:1. This close molar stoichiometry between eIF4E and PHAS-I is strongly suggestive of a role for PHAS-I in the regulation of translation in rabbit reticulocytes as well as in insulin responsive cells.


FOOTNOTES

*
This work was supported in part by grants (034710/Z/91/Z/1.5 and 040800/Z/94/Z/040) from the Wellcome Trust. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Supported by a Bursary from the University of Sussex

A Senior Research Fellow of the Wellcome Trust.

**
To whom correspondence should be addressed. Tel.: 44(0)1273 678544; Fax: 44(0)1273 678433.

(^1)
The abbreviations used are: eIF, eukaryotic initiation factor; FMDV, foot-and-mouth disease virus; m^7GTP, 7-methyl guanosine triphosphate; PRS, postribosomal supernatant; CHAPS, 3-[(cholamidopropyl)dimethylamminio]-1-propanesulfonate; Mops, 3-(N-morpholino)propanesulfonic acid; PAGE, polyacrylamide gel electrophoresis; IEF, isoelectric focusing; VSIEF, vertical-slab isoelectric focusing; RIPA, radioimmune precipitation buffer; RB, resuspension buffer; LSB, low salt buffer; RRL, rabbit reticulocyte lysate.

(^2)
M. Rau, T. Ohlmann, S. J. Morley, and V. M. Pain, unpublished data.


ACKNOWLEDGEMENTS

We are grateful to the following: Dr. J. Hershey for the anti-eIF4B antibody, Dr. M. Altmann for the monoclonal anti-eIF4A antibody, Prof. R. Denton, Dr. T. Diggle, and Dr. J. Lawrence for the anti-PHAS-I antisera, Dr. R. Rhoads for the C-terminal directed eIF4G polyclonal antibody, Dr. R. Kirchweger and Dr. T. Skern for the L protease expression vector, Dr. R. Jagus for the eIF4E expression vector, and Dr. J. Lawrence for the [His](6)PHAS-I expression vector.


REFERENCES

  1. Kozak, M. (1989) J. Cell Biol. 108, 229-241 [Abstract]
  2. Pain, V. M. (1996) Eur. J. Biochem. 236, 747-771 [Abstract]
  3. Hershey, J. W. B. (1991) Annu. Rev. Biochem. 60, 717-715 [CrossRef][Medline] [Order article via Infotrieve]
  4. Merrick, W. C. (1992) Microbiol. Rev. 56, 291-315 [Abstract]
  5. Rhoads, R. E. (1993) J. Biol. Chem. 268, 3017-3020 [Free Full Text]
  6. Merrick, W. C. (1994) Biochimie (Paris) 76, 822-831
  7. Grifo, J. A., Tahara, S. M., Morgan, M. A., Shatkin, A. J., and Merrick, W. C. (1983) J. Biol. Chem. 258, 5804-5810 [Abstract/Free Full Text]
  8. Grifo, J. A., Abramson, R. D., Satler, C. A., and Merrick, W. C. (1984) J. Biol. Chem. 259, 8648-8654 [Abstract/Free Full Text]
  9. Buckley, B., and Ehrenfeld, E. (1987) J. Biol. Chem. 262, 13599-13606 [Abstract/Free Full Text]
  10. Etchison, D., Hansen, J., Ehrenfeld, E., Edery, I., Sonenberg, N., Milburn, S., and Hershey, J. W. B. (1984) J. Virol. 51, 832-837 [Medline] [Order article via Infotrieve]
  11. Devaney, M. A., Vakharia, V. N., Lloyd, R. E., Ehrenfeld, E., and Grubman, M. J. (1988) J. Virol. 62, 4407-4409 [Medline] [Order article via Infotrieve]
  12. Ohlmann, T., Rau, M., Morley, S. J., and Pain, V. M. (1995) Nucleic Acids Res. 23, 334-340 [Abstract]
  13. Ziegler, E., Borman, A. M., Kirchweger, R., Skern, T., and Kean, K. M. (1995) J. Virol. 69, 3465-3474 [Abstract]
  14. Lamphear, B. J., Kirchweger, R., Skern, T., and Rhoads, R. E. (1995) J. Biol. Chem. 270, 21975-21983 [Abstract/Free Full Text]
  15. Mader, S., Han Lee, Pause, A., and Sonenberg, N. (1995) Mol. Cell. Biol. 15, 4990-4997 [Abstract]
  16. Ray, B. K., Lawson, T. G., Kramer, J. C., Cladaras, M. H., Grifo, J. A., Abramson, R. D., Merrick, W. C., and Thach, R. E. (1985) J. Biol. Chem. 260, 7651-7658 [Abstract/Free Full Text]
  17. Pause, A., Méthot, N., Svitkin, Y., Merrick, W. C., and Sonenberg, N. (1994) EMBO J. 13, 1205-1215 [Abstract]
  18. Duncan, R., and Hershey, J. W. B (1983) J. Biol. Chem. 258, 7228-7235 [Abstract/Free Full Text]
  19. Abramson, R. D., Dever, T. E., and Merrick, W. C. (1988) J. Biol. Chem. 263, 3826-3832
  20. Rozen, F., Edery, I., Meerovitch, K., Dever, T. E., Merrick, W. C., and Sonenberg, N. (1990) Mol. Cell. Biol. 10, 1134-1144 [Medline] [Order article via Infotrieve]
  21. Milburn, S. C., Hershey, J. W. B., Davies, M. V., Kellerher, K., and Kaufman, R. J. (1990) EMBO J. 9, 2783-2790 [Abstract]
  22. Méthot, N., Pause, A., Hershey, J. W. B., and Sonenberg, N. (1994) Mol. Cell. Biol. 14, 2307-2316 [Abstract]
  23. M é thot, N., Pickett, G., Keene, J. D., and Sonenberg, N. (1996) RNA , in press
  24. Hiremath, L. S., Webb, N. R., and Rhoads, R. E. (1985) J. Biol. Chem. 260, 7843-7849 [Abstract/Free Full Text]
  25. Goss, D. J., Carberry, S. E., Dever, T. E., Merrick, W. C., and Rhoads, R. E. (1990) Biochemistry 29, 5008-5012 [Medline] [Order article via Infotrieve]
  26. Duncan, R., Milburn, S. C., and Hershey, J. W. B. (1987) J. Biol. Chem. 262, 380-388 [Abstract/Free Full Text]
  27. Lazaris-Karatzas, A., Montine, K. S., and Sonenberg, N. (1990) Nature 345, 544-547 [CrossRef][Medline] [Order article via Infotrieve]
  28. de Benedetti, A., and Rhoads, R. E. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 8212-8216 [Abstract]
  29. Sonenberg, N. (1994) Biochimie (Paris) 76, 839-846
  30. Morley, S. J. (1994) Mol. Biol. Rep. 19, 221-231 [Medline] [Order article via Infotrieve]
  31. Morley, S. J. (1996) in Protein Phosphorylation in Cell Growth Regulation (Clemens, M. J., ed) Harwood Academic Publishers, Amsterdam, in press
  32. Bu, X., Haas, D. W., and Hagedorn, C. H. (1993) J. Biol. Chem. 268, 4975-4978 [Abstract/Free Full Text]
  33. Morley, S. J., Rau, M., Kay, J. E., and Pain, V. M. (1993) Eur. J. Biochem. 218, 39-48 [Abstract]
  34. Morley, S. J., and Pain, V. M. (1995) J. Cell Sci. 108, 1751-1760 [Abstract/Free Full Text]
  35. Bonneau, A.-M. and Sonenberg, N. (1987) J. Biol. Chem. 262, 11134-11139 [Abstract/Free Full Text]
  36. Lamphear, B. J., and Panniers, R. (1991) J. Biol. Chem. 266, 2789-2794 [Abstract/Free Full Text]
  37. Huang, J., and Schneider, R. J. (1991) Cell 65, 271-280 [Medline] [Order article via Infotrieve]
  38. Feigenblum, D., and Schneider, R. J. (1993) J. Virol. 67, 3027-3035 [Abstract]
  39. Joshi, B., Cai, A.-L., Keiper, B. D., Minich, W. B., Mendez, R., Beach, C. M., Stepinski, J., Stolarski, R., Darzynkiewicz, E., and Rhoads, R. E. (1995) J. Biol. Chem. 270, 14597-14603 [Abstract/Free Full Text]
  40. Flynn, A., and Proud, C. G. (1995) J. Biol. Chem. 270, 21684-21688 [Abstract/Free Full Text]
  41. Altmann, M., Handschin, C., and Trachsel, H. (1987) Mol. Cell. Biol. 7, 998-1003 [Medline] [Order article via Infotrieve]
  42. Metz, A. M., Timmer, R. T., and Browning, K. S. (1992) Nucleic Acids Res. 15, 4096
  43. Hernández, G., and Sierra, J. M. (1995) Biochim. Biophys. Acta 1261, 427-431 [Medline] [Order article via Infotrieve]
  44. Minich, W. B., Balasta, M. L., Goss, D. J., and Rhoads, R. E. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7668-7672 [Abstract]
  45. Lamphear, B. J. and Panniers, R. (1990) J. Biol. Chem. 265, 5333-5336 [Abstract/Free Full Text]
  46. Hu, C., Pang, S., Kong, X., Velleca, M., and Lawrence, J. C., Jr. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3730-3734 [Abstract]
  47. Pause, A., Belsham, G. J., Gingras, A.-C., Donzé, O., Lin, T.-A., Lawrence, J. C., Jr., and Sonenberg, N. (1994) Nature 371, 762-767 [CrossRef][Medline] [Order article via Infotrieve]
  48. Lin, T.-A., Kong, X., Haystead, T. A. J., Pause, A., Belsham, G., Sonenberg, N., and Lawrence, J. C., Jr. (1994) Science 266, 653-656 [Medline] [Order article via Infotrieve]
  49. Mader, S., and Sonenberg, N. (1995) Biochimie (Paris) 77, 40-44
  50. Haghighat, A., Mader, S., Pause, A., and Sonenberg, N. (1995) EMBO J. 14, 5701-5709 [Abstract]
  51. Jackson, R. J., and Hunt, T. (1983) Methods Enzymol. 96, 50-74 [Medline] [Order article via Infotrieve]
  52. Morley, S. J., and Hershey, J. W. B. (1990) Biochimie (Paris) 72, 259-264
  53. Jagus, R., Huang, W. I., Hiremath, L. S., Stern, B. D., and Rhoads, R. E. (1993) Dev. Genet. 14, 412-423 [Medline] [Order article via Infotrieve]
  54. Haystead, T. A. J., Haystead, C. M. M., Hu, C., Lin, T.-A., and Lawrence, J. C. (1994) J. Biol. Chem. 269, 23185-23191 [Abstract/Free Full Text]
  55. Kirchweger, R., Ziegler, E., Lamphear, B. J., Waters, D., Liebig, H.-D., Sommergruber, W., Sobrino, F., Hogenadl, C., Blaas, D., Rhoads, R. E., and Skern, T. (1994) J. Virol. 68, 5677-5684 [Abstract]
  56. Hansen, J. L., Etchison, D. O., Hershey, J. B. W., and Ehrenfeld, E. (1982) Mol. Cell. Biol. 2, 1639-1643 [Medline] [Order article via Infotrieve]
  57. Webb, N. R., Chari, R. V. J., DePillis, G., Kozarich, J. W., and Rhoads, R. E. (1994) Biochemistry 23, 177-181
  58. Etchison, D., and Smith, K. (1990) J. Biol. Chem. 265, 7492-7500 [Abstract/Free Full Text]
  59. Joshi-Barve, S., Rychlik, W., and Rhoads, R. E. (1990) J. Biol. Chem. 265, 2979-2983 [Abstract/Free Full Text]
  60. Lin, T.-A., Kong, X., Saltiel, A. R., Blackshear, P. J., and Lawrence, J. C., Jr. (1995) J. Biol. Chem. 270, 18531-18538 [Abstract/Free Full Text]
  61. Proud, C. G. (1994) Nature 371, 747-748 [CrossRef][Medline] [Order article via Infotrieve]
  62. Joshi, B., Yan, R., and Rhoads, R. E. (1994) J. Biol. Chem. 269, 2048-2055 [Abstract/Free Full Text]
  63. Ohlmann, T., Rau, M., Pain, V. M., and Morley, S. J. (1996) EMBO J. , in press
  64. Hiremath, L. S., Hiremath, S. T., Rychlik, W., Joshi, S., Domier, L. L., and Rhoads, R. E. (1989) J. Biol. Chem. 264, 1132-1138 [Abstract/Free Full Text]
  65. Kozak, M. (1992) Crit. Rev. Biochem. Mol. Biol. 27, 385-402 [Abstract]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.